)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
MBX Biosciences
MBX Biosciences (MBX) investor relations material
MBX Biosciences Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary8 May, 2026
Board of directors and corporate governance
Steven L. Hoerter resigned from the Audit Committee and was replaced by Edward T. Mathers effective May 1, 2026.
Board determined that all directors except P. Kent Hawryluk and Steven L. Hoerter are independent under Nasdaq and SEC rules.
Audit Committee now consists of Laurie Stelzer (Chair), Tiba Aynechi, and Edward T. Mathers.
Steven Ryder, M.D., updated as Chief Medical Officer of Yarrow Biosciences as of April 2026.
Audit committee and external auditor matters
Audit Committee membership updated following resignations and new appointments in 2025 and 2026.
Edward T. Mathers determined to be independent under Nasdaq Listing Rule 5605(a)(2) and SEC Rule 10A-3(b)(1).
Related party transactions
Company entered into a Consulting Agreement with Steven L. Hoerter, Executive Chair, effective May 1, 2026.
Consulting Agreement approved by unanimous written consent of the Board per related party transaction policy.
Mr. Hoerter received 74,249 nonqualified stock options at $29.78 and 11,938 restricted stock units as part of the agreement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MBX Biosciences
- Q1 2026 net loss narrowed, $440M cash runway into 2029, and Phase 3 trial prep advanced.MBX
Q1 20267 May 2026 - Vote on two director elections and auditor ratification at the June 2026 virtual meeting.MBXProxy filing22 Apr 2026
- Virtual meeting to elect directors and ratify auditor, with robust governance and compliance.MBXProxy filing22 Apr 2026
- Advanced clinical pipeline and raised capital, supporting operations into 2029.MBXQ4 202512 Mar 2026
- Phase III for once-weekly PTH therapy and monthly obesity treatments advance with key data in 2024.MBXBarclays 28th Annual Global Healthcare Conference11 Mar 2026
- Phase three in hypoparathyroidism advances on schedule; obesity pipeline and funding remain strong.MBXThe Citizens Life Sciences Conference 202610 Mar 2026
- Phase III and obesity data milestones, robust pipeline, and strong cash position drive outlook.MBXTD Cowen 46th Annual Health Care Conference2 Mar 2026
- Late-stage trials and new obesity programs advance, leveraging peptide tech for long-acting dosing.MBX44th Annual J.P. Morgan Healthcare Conference2 Mar 2026
- Major clinical milestones and strong financials position for leadership in endocrine and obesity therapies.MBXOppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026
Next MBX Biosciences earnings date
Status update11 May, 2026
MBX Biosciences
Next MBX Biosciences earnings date
Status update11 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage